Teva Announces Approval of Generic Actonel®
- Details
- Category: Product
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Procter and Gamble Actonel® (Risedronate Sodium) Tablets, 5 mg, 30 mg and 35 mg.
EPO Rules European Nexium® Process Patent Valid
- Details
- Category: AstraZeneca
AstraZeneca announced that the European Patent Office (EPO) Opposition Division has ruled that the European process patent EP 0773940 for Nexium® is valid in amended form, despite an opposition by the German generic manufacturer ratiopharm. The patent has been upheld as granted with regards to claims 1 and 2. Regarding claims 3 and 4, minor amendments have been made.
Aptivus® (tipranavir) capsules granted full approval by the U.S. FDA
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus® (tipranavir) capsules. The FDA granted accelerated approval to Aptivus in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.
Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
- Details
- Category: Novartis
Aclasta® (zoledronic acid 5 mg) has received European Union approval as the first once-yearly treatment for women with postmenopausal osteoporosis. The announcement closely follows the recent approval in the US, where the Food and Drug Administration (FDA) approved Aclasta under the brand name Reclast® in August 2007. The European Commission decision applies to all 27 member states, Norway and Iceland.
GSK seeks prequalification for Cervarix⢠from the World Health Organization
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it has submitted a file on its cervical cancer vaccine, Cervarix™, to the World Health Organization (WHO) for pre-qualification, following the granting of a marketing authorisation approval by regulatory authorities in Europe on 20 September.
Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that Japan's Ministry of Health, Labour and Welfare has approved ELAPRASE, a human enzyme replacement therapy for the treatment of Hunter syndrome, for sale and marketing in Japan. Since its U.S. approval in July 2006, ELAPRASE is now approved for marketing and commercial distribution in 34 countries worldwide.
Pfizer Launches Independent Biotherapeutics and Bioinnovation Center
- Details
- Category: Pfizer
Pfizer named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Dr. Corey Goodman; and named Dr. Briggs Morrison, who held senior research and development positions at Merck, as its new Head of Clinical Development for the PGRD pipeline.
More Pharma News ...
- Boehringer Ingelheim comments the nevirapine production for Rwanda by Apotex
- GSK applies for licence to market OTC weight loss product In Europe
- Herceptin eradicates tumours and may reduce the need for mastectomies
- Bionas Signs Service Contract with Solvay Pharmaceuticals
- Positive Phase 2 Results for the VEGF Trap-Eye
- Novartis and Massachusetts Institute of Technology (MIT) in new partnership
- Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation